CTMX CytomX Therapeutics Inc

Price (delayed)

$5.58

Market cap

$362.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$52.99M

Highlights
CTMX's equity has surged by 193% since the previous quarter and by 109% year-on-year
CTMX's quick ratio is up by 28% since the previous quarter and by 13% year-on-year
CytomX Therapeutics's net income has shrunk by 84% QoQ but it has increased by 20% YoY
The EPS has plunged by 73% from the previous quarter but it has grown by 27% YoY
The gross profit has declined by 34% since the previous quarter and by 14% year-on-year
CTMX's revenue is down by 34% since the previous quarter and by 14% year-on-year

Key stats

What are the main financial stats of CTMX
Market
Shares outstanding
65.01M
Market cap
$362.76M
Enterprise value
$52.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
5.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.79
Earnings
Revenue
$66.74M
EBIT
-$60.64M
EBITDA
-$54.39M
Free cash flow
$22.81M
Per share
EPS
-$1.23
Free cash flow per share
$0.37
Book value per share
$2.25
Revenue per share
$1.09
TBVPS
$7.09
Balance sheet
Total assets
$434.16M
Total liabilities
$288.14M
Debt
$20.81M
Equity
$146.02M
Working capital
$301.96M
Liquidity
Debt to equity
0.14
Current ratio
4.08
Quick ratio
4.03
Net debt/EBITDA
5.7
Margins
EBITDA margin
-81.5%
Gross margin
100%
Net margin
-90.9%
Operating margin
-92.1%
Efficiency
Return on assets
-15.4%
Return on equity
-80.1%
Return on invested capital
-94.4%
Return on capital employed
-18%
Return on sales
-90.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
-2.79%
1 week
-2.28%
1 month
-10.58%
1 year
-23.35%
YTD
-14.81%
QTD
-11.85%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$66.74M
Gross profit
$66.74M
Operating income
-$61.44M
Net income
-$60.64M
Gross margin
100%
Net margin
-90.9%
CTMX's net margin has dropped by 177% since the previous quarter but it is up by 7% year-on-year
The company's operating margin has shrunk by 90% QoQ but it rose by 26% YoY
CytomX Therapeutics's net income has shrunk by 84% QoQ but it has increased by 20% YoY
The operating income is up by 37% year-on-year but it has declined by 26% since the previous quarter

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
N/A
P/B
2.48
P/S
5.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.79
The EPS has plunged by 73% from the previous quarter but it has grown by 27% YoY
CTMX's equity has surged by 193% since the previous quarter and by 109% year-on-year
The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 8.4 and 56% less than its last 4 quarters average of 5.6
The stock's P/S is 60% less than its 5-year quarterly average of 12.8 but 13% more than its last 4 quarters average of 4.5
CTMX's revenue is down by 34% since the previous quarter and by 14% year-on-year

Efficiency

How efficient is CytomX Therapeutics business performance
The ROIC has shrunk by 123% QoQ and by 70% YoY
The ROS has plunged by 95% from the previous quarter but it has grown by 22% YoY
CTMX's return on assets has dropped by 83% since the previous quarter but it is up by 21% year-on-year
CTMX's ROE is down by 38% since the previous quarter but it is up by 20% year-on-year

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's total assets is 51% more than its total liabilities
CTMX's quick ratio is up by 28% since the previous quarter and by 13% year-on-year
The company's current ratio rose by 27% QoQ and by 8% YoY
CTMX's debt is 86% smaller than its equity
CTMX's equity has surged by 193% since the previous quarter and by 109% year-on-year
The debt to equity has dropped by 68% since the previous quarter and by 60% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.